Bicycle Therapeutics Q4 EPS $(1.16) Vs $(1.01) YoY, Sales $5.33M Miss $7.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bicycle Therapeutics reported a Q4 EPS of $(1.16), a decrease from $(1.01) YoY, and sales of $5.33M, missing the $7.14M estimate.
February 20, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bicycle Therapeutics reported a decrease in Q4 EPS from $(1.01) to $(1.16) year-over-year and missed sales estimates, reporting $5.33M against a $7.14M forecast.
The reported decrease in EPS and missed sales estimates are likely to negatively impact investor sentiment towards BCYC in the short term. Missing financial forecasts can lead to decreased confidence in the company's future performance, potentially resulting in a drop in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100